Who owns ORUKA THERAPEUTICS INC?
- CUSIP Number: 687604108
Tip: Access positions for across all investors
Analyze quarterly positions in Oruka Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Oruka Therapeutics stock
Who bought or sold ORUKA THERAPEUTICS INC this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Fairmount Funds Management | 3.2M | $79M | 100% | Sep 2024 |
|
VR Adviser | 3.1M | $76M | 100% | Sep 2024 |
|
Commodore Capital | 1.4M | $34M | 100% | Sep 2024 |
|
Perceptive Advisors | 1.2M | $30M | 100% | Sep 2024 |
|
Avidity Partners Management | 791k | $19M | 100% | Sep 2024 |
|
Franklin Resources | 721k | $20M | 100% | Sep 2024 |
|
Paradigm Biocapital Advisors | 720k | $18M | 100% | Sep 2024 |
|
Braidwell | 516k | $13M | 100% | Sep 2024 |
|
Dr. Jeffrey R. Jay, M.D. | 515k | $13M | 100% | Sep 2024 |
|
Point72 Asset Management | 482k | $12M | 100% | Sep 2024 |
|
Frazier Life Sciences Management | 477k | $12M | 100% | Sep 2024 |
|
Redmile Group | 412k | $10M | 100% | Sep 2024 |
|
Woodline Partners | 391k | $9.6M | 100% | Sep 2024 |
|
Affinity Asset Advisors | 350k | $8.6M | 100% | Sep 2024 |
|
Driehaus Capital Management | 309k | $7.6M | 100% | Sep 2024 |
|
T. Rowe Price Associates | 280k | $6.9M | 100% | Sep 2024 |
|
TD Asset Management | 95k | $2.2M | 100% | Sep 2024 |
|
Cowen And Company | 58k | $1.4M | 100% | Sep 2024 |
|
Citigroup | 27k | $655k | 100% | Sep 2024 |
|
Ensign Peak Advisors | 25k | $613k | 100% | Sep 2024 |
|
BlackRock | 22k | $529k | 100% | Sep 2024 |
|
Geode Capital Management | 14k | $343k | 100% | Sep 2024 |
|
Susquehanna International | 13k | $306k | 100% | Sep 2024 |
|
Activest Wealth Management | 166.00 | $4.1k | 100% | Sep 2024 |
|
New England Capital Financial Advisors | 41.00 | $1.0k | 100% | Sep 2024 |
|
Parallel Advisors | 20.00 | $490.000000 | 100% | Sep 2024 |
|
Bank of America Corporation | 15.00 | $367.500000 | 100% | Sep 2024 |
|